Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had its target price lifted by Morgan Stanley from $101.00 to $130.00 in a research report sent to investors on Thursday. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.
ALNY has been the subject of several other reports. Credit Suisse Group raised their target price on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an outperform rating in a research report on Friday, November 3rd. Needham & Company LLC reissued a buy rating and set a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Chardan Capital reissued a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 11th. Nomura began coverage on Alnylam Pharmaceuticals in a report on Thursday, September 14th. They set a reduce rating and a $56.00 price objective for the company. Finally, B. Riley began coverage on Alnylam Pharmaceuticals in a report on Wednesday, November 1st. They set a buy rating and a $240.00 price objective for the company. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $114.57.
Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded up $2.30 during mid-day trading on Thursday, reaching $139.98. The company had a trading volume of 1,386,900 shares, compared to its average volume of 1,120,946. Alnylam Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). The firm had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period last year, the business earned ($1.21) earnings per share. sell-side analysts predict that Alnylam Pharmaceuticals will post -5.25 earnings per share for the current fiscal year.
In other news, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dennis A. Ausiello sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $130.00, for a total value of $2,600,000.00. Following the transaction, the director now owns 20,000 shares of the company’s stock, valued at $2,600,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 215,797 shares of company stock valued at $25,035,072. Corporate insiders own 4.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of ALNY. Prudential Financial Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $215,000. Teachers Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 9.1% during the 1st quarter. Teachers Advisors LLC now owns 80,238 shares of the biopharmaceutical company’s stock worth $4,112,000 after buying an additional 6,662 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Alnylam Pharmaceuticals by 1.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 112,778 shares of the biopharmaceutical company’s stock worth $5,780,000 after buying an additional 1,428 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $2,619,000. Finally, BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock worth $243,242,000 after buying an additional 4,732,617 shares during the period. Institutional investors own 92.73% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.